Abstract: An apparatus for bulk ore sorting using gamma activation analysis is disclosed. The apparatus includes a conveyor system that includes one or more conveyor belts, surrounded by one or more radiation shields, to transport ore material along a transport path. A pulsed X-ray radiation source is configured to irradiate ore material at an irradiation region and one or more detectors are configured to detect a gamma radiation output from irradiated ore material at a detection region. The transport path has a bend, located between the irradiation region and the detection region, and about a vertical axis, of at least 45 degrees. The one or more detectors are configured to detect a radiation output from the irradiated ore material at times between X-ray pulses of the pulsed X-ray radiation source irradiating the ore material.

Abstract: Mutant mono ADP-ribose-polymerases (mono-PARP) proteins and small molecule compound substrates specific for the mutant mono-PARP proteins as well as methods of using these compositions to identify protein targets of the mono-PARPs and to screen for antagonists of the mono-PARPs are described.

Abstract: An apparatus for bulk ore sorting using gamma activation analysis is disclosed. The apparatus includes a conveyor system that includes one or more conveyor belts, surrounded by one or more radiation shields, to transport ore material along a transport path. A pulsed X-ray radiation source is configured to irradiate ore material at an irradiation region and one or more detectors are configured to detect a gamma radiation output from irradiated ore material at a detection region. The transport path has a bend, located between the irradiation region and the detection region, and about a vertical axis, of at least 45 degrees. The one or more detectors are configured to detect a radiation output from the irradiated ore material at times between X-ray pulses of the pulsed X-ray radiation source irradiating the ore material.

Abstract: Mutant mono ADP-ribose-polymerases (mono-PARP) proteins and small molecule compound substrates specific for the mutant mono-PARP proteins as well as methods of using these compositions to identify protein targets of the mono-PARPs and to screen for antagonists of the mono-PARPs are described.

Abstract: Embodiments of the present invention are directed to a system and method that can obtain a collection of wireless node data from different sources. The system and method involves a wireless location data service (WLDS) platform including a data management and a feedback module. The data management is configured to receive wireless node data through importation by a service provider. The feedback module is configured to receive wireless node data from mobile devices, engineering systems, systems generating activity logs, and third party service partners. The system and method also involves an end-user module configured to collect wireless node data and user reported corrections and transmit the collected data and corrections to the platform. A wireless node database in the platform is built and updated from the wireless node data and corrections received from the data management module and the feedback module.

Abstract: Embodiments of the present invention are directed to a system and method that can obtain a collection of wireless node data from different sources. The system and method involves a wireless location data service (WLDS) platform including a data management and a feedback module. The data management is configured to receive wireless node data through importation by a service provider. The feedback module is configured to receive wireless node data from mobile devices, engineering systems, systems generating activity logs, and third party service partners. The system and method also involves an end-user module configured to collect wireless node data and user reported corrections and transmit the collected data and corrections to the platform. A wireless node database in the platform is built and updated from the wireless node data and corrections received from the data management module and the feedback module.

Abstract: Mutant mono ADP-ribose-polymerases (mono-PARP) proteins and small molecule compound substrates specific for the mutant mono-PARP proteins as well as methods of using these compositions to identify protein targets of the mono-PARPs and to screen for antagonists of the mono-PARPs are described.

Abstract: The present invention provides (I) these compounds are useful in prevention and treatment of neurodegenerative disorders, such as Alzheimer's, Parkinson's and Huntington's as well as type II diabetes.

Abstract: The present invention relates to the compound 3,4,5-piperidinetriol, 2-(hydroxymethyl)-1-[(4-(pentyloxy)phenyl)methyl]-, (2S,3S,4R,5S), or a pharmaceutically acceptable salt or prodrug thereof, which is useful as an inhibitor of glucosylceramide synthase. The compounds of the Invention are useful for treating various glycolipid storage diseases, such as Gaucher's disease, Sandhoff's disease, Tay-Sacs disease, Fabry disease, and GM1 gangliosidosis; glycolipid accumulation disorders, such as Niemann-Pick disease, mucopolysaccharidoses, mucolipidosis type IV and ?-mannosidosis; various cancers that involve abnormal glycolipid synthesis; and various infectious diseases that involve cell surface glycolipids as receptors for the infectious organisms or for their toxins; as well as a variety of other disorders involving glycolipid synthesis, including neuronal disorders, inflammatory diseases, obesity, and the like.

Abstract: a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: wherein X and Y are independently NR5 or O; W and Z are independently a bond or (CH2)mCH(R7)(CH2)n; m=0-1, n=0-2; R is hydrogen or halogen; R1 and R2 are independently selected from hydrogen halogen, CF3, CN, OR8, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R3 is hydrogen, halogen, CF3, CN, OR8, SR8 or SO2R11; R4 is hydrogen, halogen, CF3, OR9, NR9R10, NR9COR11, NR9SO2R11 or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R5 is hydrogen or C1-6 alkyl optionally substituted by hydroxyl, C1-6 alkoxy or NR9R10; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R6 is hydrogen, fluorine, C1-6 alkyl, or C1-6 alkoxy; R7 is hydrogen, C1-6 alkyl, phenyl or C1-3 alkylphenyl wherein said phenyl groups are optionally substituted by one or more substituents selected from halogen, C1-6 alkyl, CF3, OCF3 or OR9; R8 is hydrogen or C1-6 alkyl optionally substitut

Abstract: The present invention provides (I) These compounds are useful in prevention and treatment of neurodegenerative disorders, such as Alzheimer's, Parkinson's and Huntington's as well as type II diabetes.

Abstract: A method of providing access to a communications system via a plurality of wireless hotspot access points, comprising: storing plural sets of user identification data relating to one or more wireless hotspot access points via which the user has authorization to access the communications system; using a first set of user identification data to access the communications system via a first wireless hotspot access point; and without user intervention, altering access to said communications system from being via said first hotspot access point to being via a second wireless hotspot access point, by: identifying said second wireless hotspot access point; and selecting, on the basis of said identification, a second set of user identification data, different to said first set of identification data, and using said second set of user identification data to access the communication system via said second wireless hotspot access point.

Abstract: The invention provides method of, apparatus capable of, and computer software for, providing a user with access to a communications system including a plurality of wireless access points, said method comprising providing set of functions for use on a user terminal, said functions including functions for: storing a plurality of sets of user identification data, said user identification data relating to one or more wireless access points via which the user has authorisation to access the communications system; providing a directory of wireless access points in said communications system, said directory including wireless access point identification data; using said directory to identify a wireless access point; and using one of said plurality of sets of user identification data to access the communications system via an identified wireless access point.

Abstract: The present invention relates to novel piperidine derivatives that are useful as inhibitors of glucosylceramide synthase (GCS) for use in the treatment and prevention of diseases or disorders mediated by GCS, including cancer, infectious diseases, neuronal disorders or injury and inflammatory diseases. The invention further relates to the pharmaceutical composition comprising the novel piperidine derivatives and methods for preparing the same.

Abstract: In one arrangement, a method of operating a mobile user terminal in a communications system includes monitoring received broadcast signals and deriving first identification data of fixed wireless nodes from the received broadcast signals. The method includes using data derived from a stored database in combination with the derived first identification data in order to provide a service to a user of a mobile user terminal. The method includes deriving update data from at least the derived first identification data and transmitting the derived update data to a database administration node in order to allow the stored database of fixed wireless nodes to be updated.

Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof: (I) wherein the groups Q, R2, R3, R4 and R5 represent various substituent groups, and their use as inhibitors of heparanase.

Abstract: The present invention relates to phthalimide carboxylic acid derivatives of formula (I), methods for their preparation, pharmaceutical compositions containing them and their use in medicine, specifically in the treatment of cancer. (I), wherein X is O or S; R1 is a phthalimide carboxylic acid group of formula (II).